Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E16.72 EPS (ttm)5.54 Insider Own0.10% Shs Outstand1.62B Perf Week0.84%
Market Cap149.66B Forward P/E10.57 EPS next Y8.76 Insider Trans-25.88% Shs Float1.58B Perf Month-17.65%
Income8.88B PEG1.02 EPS next Q1.80 Inst Own74.10% Short Float0.96% Perf Quarter-11.51%
Sales28.22B P/S5.30 EPS this Y52.60% Inst Trans0.03% Short Ratio1.98 Perf Half Y-3.58%
Book/sh3.19 P/B29.03 EPS next Y15.93% ROA7.80% Target Price121.38 Perf Year45.19%
Cash/sh6.06 P/C15.29 EPS next 5Y16.39% ROE92.70% 52W Range63.29 - 125.86 Perf YTD-4.25%
Dividend3.84 P/FCF28.11 EPS past 5Y10.60% ROI25.40% 52W High-26.43% Beta1.57
Dividend %4.15% Quick Ratio1.20 Sales past 5Y9.00% Gross Margin75.50% 52W Low46.31% ATR3.25
Employees29000 Current Ratio1.30 Sales Q/Q13.90% Oper. Margin34.00% RSI (14)36.38 Volatility1.97% 3.72%
OptionableYes Debt/Eq7.33 EPS Q/Q167.00% Profit Margin18.70% Rel Volume0.62 Prev Close93.01
ShortableYes LT Debt/Eq6.07 EarningsApr 26 BMO Payout77.40% Avg Volume7.71M Price92.60
Recom2.30 SMA20-0.64% SMA50-13.11% SMA200-0.72% Volume4,741,627 Change-0.44%
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Apr-20-18 09:02AM  AbbVie And Other Great Pharma And Biotech Income Stocks Simply Wall St.
Apr-19-18 02:30PM  Mylan NV Could Be Closer to a Breakout Than Most Traders Realize InvestorPlace
04:27AM  Moody's: Stable outlook for global pharmaceuticals, M&A event risk is rising Moody's
Apr-18-18 06:54PM  Roche Hemophilia Drug Gets Breakthrough Therapy Designation Zacks
08:00AM  AbbVie to Present at the Deutsche Bank's 43rd Annual Health Care Conference PR Newswire
06:47AM  The Zacks Analyst Blog Highlights: AbbVie, Berkshire Hathaway, PepsiCo, BP and Twenty-First Century Fox Zacks
Apr-17-18 03:42PM  Top Analyst Reports for AbbVie, Berkshire & PepsiCo Zacks
02:00PM  7 Stock Picks With Giant Upside: Goldman Investopedia
11:48AM  5 Drug Stocks Poised to Surpass on Earnings This Quarter Zacks
Apr-16-18 08:15AM  Consolidated Research: 2018 Summary Expectations for Amazon, Rayonier, The Boeing, Sanchez Energy, AbbVie, and American Airlines Group Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-13-18 03:20PM  Pharma Stock Roundup: NVS to Buy AveXis, PFE & ABBV's Drugs Succeed in Phase III Zacks
08:18AM  Better Buy: AbbVie Inc. vs. Eli Lilly Motley Fool
Apr-12-18 05:53PM  Mylan Fujifilm Kyowa Team Up to Market Humira Biosimilar Zacks
09:39AM  AbbVie Stock Is Signaling That a Move to the Upside Could Be Near Investopedia
Apr-11-18 11:36AM  FDA Prolongs Review Date for AbbVie Endometriosis Candidate Zacks
10:20AM  Biotech Stock Roundup: Spectrum Up, Incyte Down, AveXis to Merge with Novartis Zacks
07:50AM  Ex-Dividend Alert: Boosted its Dividend by Whopping 35%; Will Trade Ex-Dividend on April 12, 2018 ACCESSWIRE
06:03AM  Is Gilead Sciences, Inc. (GILD) a Buy? Motley Fool
Apr-10-18 04:40PM  AbbVie's RA Candidate Meets Primary Endpoints in Phase III Zacks
10:16AM  FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  UPDATE 1-FDA needs more time to review AbbVie, Neurocrine's uterine pain drug Reuters
09:05AM  FDA extends review for AbbVie, Neurocrine's uterine pain drug Reuters
08:15AM  AbbVie and Neurocrine Biosciences Announce PDUFA Target Date of Q3 2018 for Elagolix in Endometriosis-Associated Pain PR Newswire
Apr-09-18 08:54AM  AbbVie shares jump 2.2% on news of positive results in rheumatoid arthritis drug trial MarketWatch
08:45AM  Upadacitinib Meets All Primary and Ranked Secondary Endpoints Including Superiority Versus Adalimumab in Phase 3 Study in Rheumatoid Arthritis PR Newswire
06:00AM  3 Reasons This Clinical-Stage Biotech Is an Incredible Bargain Motley Fool
01:37AM  [$$] Merck eyes best day since 2016, gains help fuel pharma rally Financial Times
Apr-08-18 04:26PM  Here's Why AbbVie Inc. Fell 18.3% in March Motley Fool
Apr-06-18 07:45PM  3 High-Yield Stocks at Rock-Bottom Prices Motley Fool
11:06AM  Biogen Cracks the Case With AbbVie for Humira Biosimilar Zacks
08:00AM  AbbVie to Host First-Quarter 2018 Earnings Conference Call PR Newswire
06:00AM  Cancer killer: Tampas best-kept secret M2Gen collects data from labs and bedsides to help target treatments American City Business Journals
Apr-05-18 08:50PM  [$$] Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira The Wall Street Journal
02:43PM  MARKETS: Stocks bust higher, Facebook fake out, Boeing bump, financials turn green Yahoo Finance Video
02:26PM  AbbVie Once Again Settles to Protect Humira Franchise From Biosimilars TheStreet.com
12:44PM  Tracking the traders' Q1 moves CNBC Videos
12:34PM  AbbVie, Samsung Bioepis in deal; Humira biosimilar U.S. release in 2023 Reuters
11:21AM  AbbVie Deal Allows Biogen To Launch Humira Copy In Europe Investor's Business Daily
10:13AM  [$$] Samsung, Biogen Reach Deal With AbbVie to Sell Near Copy of Humira The Wall Street Journal
09:42AM  AbbVie in deal with Biogen to delay Humira biosimilar U.S. launch to 2023 Reuters
08:05AM  AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Samsung Bioepis PR Newswire
12:15AM  [$$] A look at the biggest bets in biotech land (spoiler alert: many ended badly) Financial Times
Apr-04-18 11:08AM  Top 5 Biotech Stocks for 2018 Investopedia
06:02AM  Which Big Pharma CEOs Least Deserved Their Big Pay Increases? Motley Fool
Apr-03-18 11:49PM  [$$] Investors smart at ailing pharma deals Financial Times
08:03PM  Better Dividend Stock to Buy: AbbVie Inc. vs. Pfizer Inc. Motley Fool
06:34AM  2 Big Biotech Bargains You Can Buy Now Motley Fool
Apr-02-18 07:19PM  Top 4 Marijuana Stocks to Watch Investopedia
Apr-01-18 10:31AM  How Safe Is AbbVie, Inc.'s Dividend Now? Motley Fool
07:18AM  Better Buy: AbbVie Inc. vs. Johnson & Johnson Motley Fool
06:58AM  Cannabis Investing: 2 of the Easiest Stocks to Buy to Play the Legal Weed Boom TheStreet.com
Mar-30-18 08:18AM  Do drug prices affect CEO pay? Faith-based investor group wants to know MarketWatch
06:18AM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
Mar-29-18 06:41PM  Geron Corp. Skyrocketed and AbbVie Inc. Crashed -- Are These Stocks Buys? Motley Fool
02:28PM  AbbVie Has a Growing Credibility Problem Bloomberg
Mar-28-18 10:37AM  When Will They Learn? 4 Huge Biotech Blowups Motley Fool
07:00AM  It's Not Final 4 But WashU, Wisconsin Fight on Other Court Bloomberg
06:04AM  3 Biotechs That Could Get Big Boosts in April Motley Fool
Mar-27-18 06:32AM  How Risky Is AbbVie's Pipeline? Motley Fool
Mar-26-18 05:33PM  U.S. jury orders AbbVie to pay $3 mln in AndroGel retrial Reuters
04:31PM  The Biggest Movers: Microsoft Shines; AbbVie Slumps Barrons.com
06:41AM  The Zacks Analyst Blog Highlights: AbbVie, J&J, Heron Therapeutics, Roche and Pfizer Zacks
Mar-24-18 09:50AM  Weekend roundup: Facebook | Trade wars | AbbVies costly disappointment MarketWatch
Mar-23-18 05:05PM  Is AbbVie 'Unraveling' In Solid Tumor Market After Drug Misstep? Investor's Business Daily
04:22PM  Pharma Stock Roundup: ABBV's Rova-T Disappoints, J&J Unit Gets Buyout Offer Zacks
10:28AM  Cancer Space Roundup: NVS' Tasigna & SGEN's Adcetris Label Expansions in Focus Zacks
08:16AM  Is AbbVie Still a Buy After Its Rova-T Setback? Motley Fool
08:10AM  AbbVie stock slammed after disappointing results for cancer drug acquired in $5.8 billion deal MarketWatch
08:10AM  Todays Research Reports on Stocks to Watch: AbbVie and Pfizer ACCESSWIRE
08:09AM  AbbVies latest trial data was probably worse than it looked MarketWatch
07:10AM  AbbVie (ABBV) Stock Falls on Weak Lung Cancer Study Outcome Zacks
05:22AM  Is The AbbVie Dip A Buying Opportunity? Market Exclusive
Mar-22-18 11:02PM  Asian shares slump on fears of trade war between US, China Associated Press -12.76%
08:56PM  Stocks dive on trade war fears after China sanctions Associated Press
08:30PM  Is It Game Over for AbbVie's Promising Cancer Drug? Motley Fool
08:00PM  AbbVie Dip Presents Rare Buying Opportunity; Activist Steps Up at SuperValu TheStreet.com
05:03PM  What Happened in the Stock Market Today Motley Fool
04:41PM  US STOCKS-Stocks tumble to worst day in six weeks after Trump tariff action Reuters
04:40PM  The Biggest Movers: Everyone Loves Utilities Barrons.com
04:31PM  Caterpillar and Bank of America sink; Guess surges Associated Press
04:18PM  Stock Market Dives On Trade War Fears As China, Chip Stocks Hit Hard Investor's Business Daily
03:12PM  AbbVie Inc. -- Moody's: AbbVie's Rova-T results credit negative Moody's
03:08PM  A $158 Billion Drug Giant Faces an Identity Crisis Bloomberg
02:38PM  AbbVie Tumbles 12% on Drug Reversal Barrons.com
02:11PM  AbbVie's Cancer Drug Setback Provides Buying Opportunity TheStreet.com
12:51PM  AbbVie's Lung Cancer Drug Falls Short in Tests Investopedia
12:47PM  Peter Thiel's Firm Backed A Biotech. Big Pharma Bought It. It Blew Up Forbes
12:07PM  AbbVie Inc Stock Dives on Lung Cancer Drug Results InvestorPlace
11:32AM  Why Is AbbVie (ABBV) Stock Crashing Today? Zacks
11:31AM  AbbVie's lung cancer drug data disappoints; shares slump Reuters
11:00AM  This Explains Why AbbVie Is Falling Today Motley Fool
10:04AM  UPDATE: AbbVie shares plummet 11.7% on cancer drug results MarketWatch
09:29AM  Stocks to Watch: Facebook, Amazon, AbbVie, Accenture, Darden, Pandora, Conagra, Guess The Wall Street Journal
08:45AM  AbbVie Announces Results from Phase 2 Study Evaluating Rovalpituzumab Tesirine (Rova-T) for Third-Line Treatment of Patients with DLL3-Expressing Relapsed/Refractory Small Cell Lung Cancer PR Newswire
Mar-21-18 11:05PM  [$$] AbbVie in $25bn wipeout after cancer drug results Financial Times
09:12AM  Drug prices continue to climb despite barrage of criticism CNBC
09:00AM  AbbVie and the International Myeloma Foundation Announce Partnership to Study the Role of a Genetic Mutation in Outcomes of Patients with Multiple Myeloma PR Newswire
Mar-20-18 06:31AM  3 Healthcare Stocks Hedge Funds Like the Most Motley Fool
Mar-19-18 10:41AM  J&J Gets $2.1B Offer for LifeScan Diabetes Device Unit Zacks
08:34AM  The Zacks Analyst Blog Highlights: Biogen, AbbVie, Novartis, Teva and Celgene Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has a strategic collaboration with Alector, Inc.; C2N Diagnostics; Voyager Therapeutics, Inc.; Janssen Biotech, Inc.; and International Myeloma Foundation. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ALBAN CARLOSEVP, Commercial OperationsMar 01Option Exercise29.2348,1001,405,795178,547Mar 02 05:29 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Option Exercise25.9132,400839,339197,263Mar 02 05:28 PM
Schumacher Laura JExecutive Vice PresidentMar 01Sale117.8525,0002,946,14898,317Mar 02 05:28 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMar 01Sale114.5032,4003,709,687164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsMar 01Sale114.3980,9959,264,80897,552Mar 02 05:29 PM
Michael Robert A.VP, ControllerFeb 28Sale119.434,294512,8536,876Mar 02 05:31 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 28Sale117.771,337157,45893,312Mar 02 05:31 PM
SEVERINO MICHAELEVP, R&D and CSOFeb 28Sale117.932,643311,684132,281Mar 02 05:30 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesFeb 28Sale118.6718,1292,151,45217,588Mar 02 05:30 PM
CHASE WILLIAM JEVP, Chief Financial OfficerFeb 28Sale119.4438,5284,601,954164,863Mar 02 05:28 PM
ALBAN CARLOSEVP, Commercial OperationsFeb 28Sale117.852,579303,928130,447Mar 02 05:29 PM
GONZALEZ RICHARD AChairman of the Board and CEOFeb 28Sale117.888,280976,084313,012Mar 02 05:28 PM
Michael Robert A.VP, ControllerFeb 20Sale120.31992119,35113,557Feb 20 06:08 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Option Exercise35.8887,0403,122,995113,118Dec 19 06:09 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesDec 18Sale98.4587,0408,569,05326,078Dec 19 06:09 PM
Schumacher Laura JExecutive Vice PresidentDec 15Option Exercise35.881,14341,011106,875Dec 15 05:13 PM
Schumacher Laura JExecutive Vice PresidentDec 14Option Exercise35.88144,3675,179,888250,099Dec 15 05:13 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Option Exercise58.88218,19312,847,204492,030Nov 24 04:55 PM
GONZALEZ RICHARD AChairman of the Board and CEONov 21Sale94.01218,19320,511,800273,837Nov 24 04:55 PM
SEVERINO MICHAELEVP, R&D and CSONov 10Sale94.6925,6332,427,212114,922Nov 13 05:26 PM
Gosebruch Henry OChief Strategy OfficerOct 30Sale90.5518,3001,657,03765,137Oct 31 05:04 PM
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM